<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03292965</url>
  </required_header>
  <id_info>
    <org_study_id>B-1609-363-002</org_study_id>
    <nct_id>NCT03292965</nct_id>
  </id_info>
  <brief_title>Monitoring of Postoperative Residual Neuromuscular Blockade in Laparoscopic Surgery</brief_title>
  <official_title>Monitoring of Postoperative Residual Neuromuscular Blockade in Laparoscopic Surgery: Comparison of Neostigmine and Sugammadex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the reversal effect of neostigmine and sugammadex using quantitative neuromuscular
      monitoring
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the end of surgery, decide the dosage of reversal referring to quantitative neuromuscular
      monitoring value (TOF). After the administration of reversal, the anesthesiologist who are
      going to manage the participant should not check the quantitative neuromuscular monitoring
      and determine the timing of extubation only with his (or her) judgement. After entering
      post-anaesthesia care unit (PACU) measure the TOF value and check the incidence of TOF ratio
      &gt; 0.9 between the neostigmine group and sugammadex group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 17, 2017</start_date>
  <completion_date type="Actual">November 29, 2017</completion_date>
  <primary_completion_date type="Actual">November 29, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the incidence of postoperative residual curarization</measure>
    <time_frame>Immediately after entering PACU</time_frame>
    <description>definition of postoperative residual curarization: TOF ration is 0.9 or over 0.9</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Neuromuscular Block, Residual</condition>
  <arm_group>
    <arm_group_label>Neostigmine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At the end of surgery, administrating neostigmine to participants according to the protocol below:
when train-of-four (TOF) 2-3, administrating neostigmine 50mcg/kg when TOF 4 with fade, administrating neostigmine 40mcg/kg when TOF 4 without fade, administrating neostigmine 20mcg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At the end of surgery, administrating sugammadex to participants according to the protocol below:
when TOF=0 and post-tetanic count (PTC)=1 or more, administrating sugammadex 4mg/kg when TOF=1 or more, administrating sugammadex 2mg/kg when TOF 4 without fade, administrating neostigmine 20mcg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>Referring to the randomisation allocation program, participants allocated to group neostigmine, administrate neostigmine as reversal</description>
    <arm_group_label>Neostigmine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Referring to the randomisation allocation program, participants allocated to group sugammadex, administrate sugammadex as reversal</description>
    <arm_group_label>Sugammadex</arm_group_label>
    <other_name>Bridion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients aged over 18 years, planned to undergoing elective laparoscopic surgery under
             general anesthesia

        Exclusion Criteria:

          -  Obesity BMI over 30 kg/m2

          -  Impairment of renal or/and liver function

          -  Allergy to rocuronium, sugammadex

          -  (Familial) history of malignant hyperthermia

          -  Taking medicines which is affecting neuromuscular function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AhYoung Oh, M.D Ph. D</last_name>
    <role>Study Chair</role>
    <affiliation>Department of anesthesiology and pain medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2017</study_first_submitted>
  <study_first_submitted_qc>September 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2017</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>LEE YEA JI</investigator_full_name>
    <investigator_title>clinical professor of department of anesthesiology and pain medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delayed Emergence from Anesthesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

